HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

<p>Abstract</p> <p>Background</p> <p>The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovari...

Descrición completa

Detalles Bibliográficos

Principais autores:	Swenerton Kenneth D, Kalloger Steve E, Köbel Martin, Adamiak Anna, Ronnett Bridgett M, Vang Russell, Wiegand Kimberly C, McAlpine Jessica N, Huntsman David G, Gilks C, Miller Dianne M
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2009-12-01
Series:	BMC Cancer
Acceso en liña:	http://www.biomedcentral.com/1471-2407/9/433
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!